<ѻý>AI Blood Test Proves Useful in Lung Cancer Detectionѻý> Such an approach would be useful considering the barriers to LDCT among high-risk people Aug 25, 2021
<ѻý>Avoiding Hippocampus in Brain RT May Help Preserve Cognitive Functionѻý> Recall metrics favored hippocampal avoidance at all time points, with no increase in brain mets Aug 13, 2021
<ѻý>Kathy Griffin's Early-Stage Lung Cancerѻý> A closer look at diagnosis in "never-smokers" Aug 09, 2021
<ѻý>Drug Combo Promising in Rare Mesotheliomaѻý> Small study showed "robust and durable" responses, with "meaningful prolongation of survival" Jul 19, 2021
<ѻý>Juul Bought Out Medical Journal for $51Kѻý> E-cig maker sponsored nearly a dozen studies, took over journal as it awaits FDA ruling Jul 13, 2021
<ѻý>LDCT Screening Linked to Lower Risk of Brain Mets in Lung Cancerѻý> This observed reduction in risk may be due to a less aggressive tumor biology, said study author Jun 28, 2021
<ѻý>Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survivalѻý> News, features, and commentary about cancer-related issues Jun 16, 2021
<ѻý>Bispecific Antibody Active in NRG1-Positive Pancreatic Cancerѻý> Zenocutuzumab turns in promising results in early-phase trial involving multiple solid tumors Jun 10, 2021
<ѻý>Combination Shows Promise in Post-Osimertinib Lung Cancerѻý> Responses in 36% with amivantamab-lazertinib, 47% with EGFR/MET resistance Jun 06, 2021
<ѻý>Antibody-Drug Conjugate Active in Resistant Lung Cancerѻý> Responses in 39% of EGFR inhibitor-resistant patients with patritumab deruxtecan Jun 05, 2021
<ѻý>Chemoimmunotherapy Tied to Better Outcomes in Advanced NSCLCѻý> PD-L1 status and age play key roles in success of combined regimen versus immunotherapy alone Jun 05, 2021
<ѻý>Lymph Node Findings on PET: Cancer or COVID Vaccine?ѻý> Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
<ѻý>Anti-PD-L1 Plus SBRT Enhances Major Responses in Early NSCLCѻý> Neoadjuvant combo needs to be validated in a larger randomized trial May 20, 2021
<ѻý>PD-L1 Inhibitor Thwarts Recurrence in Early Lung Cancerѻý> Risk of death, recurrence 34% lower with atezolizumab after surgery and chemo May 19, 2021
<ѻý>Op-Ed: Is FDA's Cigarette Ban Just Smoke and Menthols?ѻý> Actually implementing a ban on menthol cigarettes and cigars could take years May 03, 2021
<ѻý>SBRT Safe for Cancer Patients With Multiple Metastasesѻý> Late adverse events in phase I trial indicate need for extended follow-up May 03, 2021
<ѻý>Lung Cancer Survival Continues to Rise With Immunotherapyѻý> Twice as many patients with advanced NSCLC alive at 5 years with pembrolizumab vs chemo Apr 29, 2021
<ѻý>New Anti-PD1 Drugs Boost Survival in Treated Lung Cancerѻý> Questions about generalizability of results with China-developed therapies Apr 14, 2021
<ѻý>A Win for Nivolumab as Preoperative Therapy for Lung Cancerѻý> Pathologic CR rate 12 times higher with the addition of anti-PD-1 agent to chemo Apr 11, 2021
<ѻý>USPSTF Expands Lung Cancer Screening Criteriaѻý> Lower age for starting, new definition of 'heavy smoker' double eligibility for screening Mar 09, 2021
<ѻý>Entrectinib Impresses in Certain Lung Cancersѻý> Durable responses in most patients with advanced NSCLC, active in brain mets Mar 05, 2021
<ѻý>New Targeted Therapies Show Promise in Cancerѻý> Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
<ѻý>Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLCѻý> More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab. Feb 18, 2021
<ѻý>New Drug OK'd for Chemo-Induced Myelosuppression in SCLCѻý> CDK4/6 inhibitor cut the risk for severe neutropenia in small-cell lung cancer patients Feb 13, 2021
<ѻý>Dustin Diamond's Small Cell Lung Cancerѻý> "Saved by the Bell" actor diagnosed after exhaustive testing Feb 02, 2021
<ѻý>KRAS Inhibitor Continues to Impress in NSCLCѻý> Sotorasib yielded deep and durable responses in over one-third of patients Feb 01, 2021
<ѻý>Nab-Paclitaxel as Possible Option for Relapsed NSCLCѻý> Noninferior to docetaxel for OS, though impact on clinical practice questioned Feb 01, 2021
<ѻý>Should COVID-Strained Centers Hit Pause on Lung Cancer Screening?ѻý> A debate on what stopping scans would do to health systems, patients Feb 01, 2021
<ѻý>Promising Data for Preop Checkpoint Inhibition in NSCLCѻý> Major response rate of 21%, encouraging survival with single-agent atezolizumab Jan 31, 2021
<ѻý>First-Ever Survival Bump in Relapsed Mesotheliomaѻý> OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
<ѻý>Dual Checkpoint Blockade No Help in PD-L1-High NSCLCѻý> Single-agent pembrolizumab wins out as first-line therapy for advanced disease Jan 30, 2021
<ѻý>COVID Affects Cancer Care, Patients' Mental Healthѻý> Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
<ѻý>Montana Oncologist Fired for Misdiagnosing, Overtreating Patientsѻý> But some rally around him Jan 26, 2021
<ѻý>Cancer and COVID; Booze and Cancer; 'Screech' Starts Chemoѻý> News, features, and commentary about cancer-related issues Jan 21, 2021
<ѻý>Targeted Combo Fails in EGFR-Mutant NSCLCѻý> Osimertinib-bevacizumab no better than osimertinib alone Jan 07, 2021
<ѻý>Baby Boys Get Cancer From Mom During Birthѻý> Report highlights potential fetal implications of undiagnosed maternal cervical cancer Jan 06, 2021
<ѻý>Lorlatinib Shows 'Striking' CNS Activity in ALK Lung Cancerѻý> But unusual adverse events may hold therapy back Nov 18, 2020
<ѻý>CDK4/6 Inhibitor in SCLC Cuts Chemo-Induced Myelosuppressionѻý> Reduced severe neutropenia and less need for supportive care with trilaciclib Oct 20, 2020
<ѻý>Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLCѻý> Nivolumab-ipilimumab with two cycles of chemotherapy improved survival, regardless of histology or PD-L1 status Oct 17, 2020
<ѻý>Drug Active in 'Undruggable' KRAS-Mutant NSCLCѻý> Responses in a third of patients, disease control rate approaching 90% Sep 20, 2020